Kezar Life Sciences, Inc. (NASDAQ:KZR) Expected to Post FY2024 Earnings of ($1.19) Per Share

Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – HC Wainwright issued their FY2024 earnings estimates for Kezar Life Sciences in a report released on Thursday, March 16th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.19) per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.15) per share.

Other equities analysts also recently issued reports about the stock. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday. Wells Fargo & Company decreased their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, January 3rd.

Kezar Life Sciences Stock Performance

Shares of NASDAQ:KZR opened at $3.76 on Friday. The company has a market cap of $266.22 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The company has a 50-day moving average price of $6.21 and a 200-day moving average price of $7.26. The company has a current ratio of 25.98, a quick ratio of 31.15 and a debt-to-equity ratio of 0.04. Kezar Life Sciences has a 12 month low of $3.55 and a 12 month high of $18.55.

Insiders Place Their Bets

In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 5,000 shares of the company’s stock in a transaction dated Thursday, January 12th. The shares were sold at an average price of $6.77, for a total value of $33,850.00. Following the sale, the insider now owns 5,881,078 shares in the company, valued at $39,814,898.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 248,276 shares of company stock worth $1,708,683. 7.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kezar Life Sciences

A number of institutional investors have recently made changes to their positions in the company. Avidity Partners Management LP grew its holdings in shares of Kezar Life Sciences by 25.3% during the fourth quarter. Avidity Partners Management LP now owns 6,782,400 shares of the company’s stock valued at $47,748,000 after buying an additional 1,368,000 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Kezar Life Sciences by 14.7% during the third quarter. BlackRock Inc. now owns 4,104,929 shares of the company’s stock valued at $35,343,000 after buying an additional 525,139 shares during the last quarter. State Street Corp grew its holdings in shares of Kezar Life Sciences by 381.3% during the third quarter. State Street Corp now owns 3,537,701 shares of the company’s stock valued at $30,460,000 after buying an additional 2,802,611 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kezar Life Sciences by 22.8% during the third quarter. Vanguard Group Inc. now owns 2,993,207 shares of the company’s stock valued at $25,771,000 after buying an additional 556,020 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Kezar Life Sciences during the second quarter valued at approximately $11,735,000. Hedge funds and other institutional investors own 84.03% of the company’s stock.

About Kezar Life Sciences

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.